Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Curr Hypertens Rev. 2021;17(3):228–237. doi: 10.2174/1573402116666200817113125

Table 3:

Baseline characteristics of participants included in eGFR analysis (study A and B combined)

Characteristic Total (n= 671) Serum uric acid (mg/dL) P value
Low (≤ 5.7) (n= 230) Medium (5.71-7.39) (n= 214) High (≥7.4) (n= 227)
Age (years), mean (std) 45 (10) 44 (10) 45 (10) 47 (10) < 0.01
White, n (%) 635 (95) 218 (95) 205 (96) 212 (93) 0.53
Male, n (%) 333 (50) 54 (23) 119 (56) 160 (70) < 0.001
BMI (kg/m2), mean (std) 27.6 (5.0) 26.2 (4.8) 27.4 (4.6) 29.1 (5.1) < 0.001
SUA (mg/dL), mean (std) 6.7 (2.0) 4.6 (0.8) 6.5 (0.4) 9.0 (1.4) < 0.001
SBP, mean (std) 116 (12) 115 (12) 117 (12) 117 (13) 0.10
DBP, mean (std) 74 (9) 74 (10) 74 (9) 75 (9) 0.56
eGFR (mL/min/1.73 m2), mean (std) 63 (28) 78 (26) 62 (27) 50 (23) < 0.001
Ualbum (mg/24 hours), median (IQR) 17 (8-39) 15 (7-29) 16 (8-37) 23 (10-62) < 0.001
GenoType 0.04
PKD1-T, n (%) 335 (50) 112 (49) 108 (51) 115 (51)
PKD1-NT, n (%) 181 (27) 48 (21) 65 (30) 68 (30)
PKD2, n (%) 111 (17) 49 (21) 30 (14) 32 (14)
NMD, n (%) 44 (7) 21 (9) 11 (5) 12 (5)
Treatment, n (%) 339 (51) 113 (49) 110 (51) 116 (51) 0.87
Current smoking, n (%) 51 (8) 14 (6) 16 (7) 21 (9) 0.44
Diuretic use, n (%) 94 (14) 24 (10) 33 (15) 37 (16) 0.15
Allopurinol use, n (%) 39 (6) 12 (5) 9 (4) 18 (8) 0.22

BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated GFR using the CKD-EPI equation; IQR: interquartile range; NMD: no mutation detected; PKD1-T: truncating PKD1 mutation; PKD1-NT: nontruncating PKD1 mutation; PKD2: PKD2 mutation; SBP: systolic blood pressure; std: standard deviation; SUA: serum uric acid; treatment: randomized to lisinopril + telmisartan; Ualbum: urinary albumin excretion.

The P values are based on analysis of variance (ANOVA) for continuous variables and the Chi-square test for categorical variables. For Ualbum the log value was used.